Find an expert

Alexandra is jointly-appointed as Professor of Clinical Nursing, University of Queensland and Mater Health Services. She has practised extensively in acute cancer care, including chemotherapy administration, in rural and metropolitan settings. Her PhD investigated sociocultural issues related to breast cancer and while she mostly now undertakes intervention research, she maintains an interest in the sociological as well as clinical aspects of cancer care. Sandie’s current funded research has two streams. The first stream focuses upon issues related to the long term outcomes of cancer treatments, using mixed methods. The second stream concentrates on collaborative interventions to assess and manage the toxicities of acute cancer treatments.

Greg studies cellular signalling in disease and the identification of new drug targets. Greg leads the Calcium Signalling Therapeutics Team (CaSTT) in the School of Pharmacy at UQ.

His lab specializes in the development and application of genetically encoded calcium indicators for high-content imaging in live cells. His team focuses on integrating these technologies into high-throughput assays that are critical for drug discovery efforts targeting calcium-mediated signaling pathways. The group has developed and utilized high-content imaging platforms to investigate calcium signaling in various cell types. These platforms enable the team to conduct large-scale screenings and these have been instrumental in identifying novel therapeutic targets.

Greg has established a research program with research funding via NHMRC, ARC, Queensland Cancer Council, Society of Biomolecular Screening, Department of Defense (USA) and other grants and collaboration with Pharmaceutical companies. His interests are signal transduction in disease, calcium transporters as drug targets and biomolecular screening. His work has led to patents and projects towards commercialization for new therapies for cancer.

In 2006 he received a UQ Foundation research excellence award and in 2016 he received the UQ Research Higher Degree Supervision Excellence Award - video link. Greg has also recieved a Research Mentorship Award (HaBS, 2017) and an award for Excellence in Leadership (UQ, 2016).

Dr Dominic Ng graduated with a BSc (Hons) and gained his PhD from the University of Western Australia. His doctoral studies, conducted in the laboratory of Assoc. Prof. Marie Bogoyevitch, were focused on cardiomyocyte signalling mechanisms regulating pathological tissue growth (ie cardiac hypertrophy). He continued his research training in Singapore as a post-doctoral research fellow based at the Institute of Molecular and Cell Biology, the flagship institute of Singapore’s science agency (A*STAR) located at the world renowned Biopolis research precinct. During this time, his research interests turned to the complex regulation of the cytoskeleton and their functions in development and disease.

He returned to the Australian medical research community on an NHMRC Peter Doherty Fellowship (2006-2010) followed by a Faculty Trust Roper Fellowship (2011-2012). In this time, Dominic established an independent research program focused on complex signalling regulation of microtubule organization. In 2013, Dominic was appointed as a Senior Research Fellow, supported by an ARC Future Fellowship (2013-2016) at the Department of Biochemistry within the Bio21 Institute, University of Melbourne. In 2015, Dominic relocated his research group to the School of Biomedical Science, University of Queensland and is currently appointed as an ARC Future Fellow and Senior Lecturer.

Professor Obermair is the Director of Queensland Centre for Gynaecological Cancer Research (QCGC Research). He is a Professor of Gynaecological Oncology since 2007, a Senior Medical Officer at Royal Brisbane & Women’s Hospital and a Visiting Medical Officer at St Andrews War Memorial Hospital and Buderim Private Hospital. He holds an Honorary title of Professor at UQ since 2006.

Professor Obermair is an internationally recognised leader in gynaecological oncology research and treatment and has lead the research team at QCGC Research since establishing it in 2003.

Dr Gerry Olive is a Queensland trained Respiratory Physician and early career researcher, undertaking a PhD in the field of lung cancer diagnosis. He has a keen clinical and research interest in the diagnostic approach to nodules and diagnostic bronchoscopy, including endobronchial ultrasound.

Dr Natacha Omer is a paediatic oncologist at the Queensland Children's Hospital in Brisbane. She is specialised in solid tumours, with a spacial interest in paediatric and adolescent sarcomas, cancer immunotherapy and molecular oncology. She is undertaking a PhD in immunology studying natural killer (NK) cell immunotherapy in paediatric sarcomas at the Frazer Institute, University of Queensland, in Dr Fernando Guimaraes lab.

Chiara is Professor in Veterinary Pathology at the School of Veterinary Science (SVS) of the University of Queensland (UQ). She is a board certified specialist veterinary pathologist (Diplomate of the European College of Veterinary Pathology), graduated with a DVM from the University of Teramo (Italy) in 2002 and a PhD in Ultrastructural Pathology in 2006. Before joining UQ in 2012, she has been working as an Assistant Professor in Veterinary Pathology at the University of Teramo (Italy). She has a specific research interest is small animal oncology, in particular canine prostate cancer, and veterinary oncoepidemiology. She is Chair of the canine prostate cancer subgroup at the Oncology Pathology Working Group (OPWG), co-coordinator of the Global Initiative for Veterinary Cancer Surveillance (GIVCS) committee for the establishment of international standards of veterinary cancer registration and team leader of the comparative oncology theme of the Queensland Alliance of One Health Science. She is also member of the board of the Veterinary Cancer Guidelines and Protocols (VCGP) group, member of the Oncology Committee of the World Small Animal Veterinary Association (WSAVA) and chair of the ESVP/ECVP DEI task force. She is past President of the Australian Society for Veterinary Pathology and, within UQ SVS, she has been postgraduate coursework coordinator (2014-2017), HDR coordinator (2017-2019) and Director of Research (2019-2021). She is now coordinator of the UQ SVS veterinary pathology postgraduate training program. She has received several academic awards, including SVS awards for research excellence (2017, 2021), best lecturer (2021, 2022, 2023, 2024), and UQ award for excellence in HDR supervision (2020). She has published more than 120 papers on international journals, 3 book chapters and numerous abstracts in proceedings of national and international conferences. She has > 15 years expertise in veterinary diagnostic pathology, histopathology, IHC and TEM in multiple species. Since her first academic appointment in 2005, she mentored several postgraduate and undergraduate students in diagnostic investigation of animal cancer and research in canine oncology. Although outside the field of comparative oncology, she also a unique expertise in avian pathology and transmission electron microscopy.

Marie-Odile Parat (MO) joined the School of Pharmacy as Senior Lecturer in December 2007.

MO obtained her Pharm.D. from University Joseph Fourier in Grenoble, France, a Masters in Cutaneous Biology from University Claude Bernard in Lyon, France and her Ph.D. in Cell Biology from University Joseph Fourier in Grenoble, France. She further has post graduate diplomas in the fields of Biomedical and Industrial Pharmacy, Photobiology, Pharmaceutical Management, and Public Health.

MO did her Pharmaceutical Residency at the University Hospitals of Grenoble, France in the Sterile Pharmaceutical Supplies Headquarters, the Department of Nuclear Medicine, and the Laboratory Medicine Department of Biochemistry. Attracted by international working experience, she carried out research within the R&D laboratories of Estee Lauder in Melville, NY. She further worked for the United Nations International Trade center in Geneva, Switzerland, where she was the Product Specialist on market information for pharmaceutical raw materials/essential drugs for three years in collaboration with the World Health Organization.

She later performed post-doctoral research in the Universidade de São Paulo, SP, Brasil and The Cleveland Clinic Foundation in the United States. She was appointed as a Staff Scientist in the Center for Anesthesiology Research of the Cleveland Clinic in 2003, an Assistant Professor of Molecular Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and a Member of the Case Cancer Center.

During her research career MO has attracted awards from various funding agencies including the Research Funding Agency of the State of São Paulo (FAPESP), the American Heart Association, the Ohio Cancer Research Associates, the American Cancer Society, the National Heart Foundation of Australia, Cancer Council Queensland, Australian and New Zealand College of Anaesthetists and the Australia Research Council (ARC).

The long term goal of the Parat laboratory is to provide insight for novel cancer therapies. A basic science team focusses on endothelial and cancer cell migration, invasion, angiogenesis, and specialized plasma membrane subdomains termed caveolae. A translational axis of research evaluates novel mechanisms by which opioids administered to cancer patients modulate the risk of long term tumour recurrence and metastasis.

Profile Summary

Dr Sandro Porceddu is an internationally recognised radiation oncologist and a leading authority in head and neck and skin cancer. With over 20 years experience in medicine his areas of clinical expertise include head and neck cancer, skin cancer, sarcoma and lymphoma. He is currently a senior radiation oncologist and Director of radiation oncology research at the Princess Alexandra Hospital, Brisbane, Professor of Medicine, University of Queensland and Associate Editor for the International Head and Neck journal, Oral Oncology.

Dr Porceddu is a nationally and internationally recognised cancer advocate through his involvement in high-level committees, engagement with key policymakers, community education and media roles.

Career Summary

Professor Porceddu completed his medical degree at Monash University before undertaking his residency at Monash Medical Centre, Melbourne. He commenced his specialist training in radiation oncology at the Peter MacCallum Cancer Centre in 1996 and was made Fellow of the Royal Australian and New Zealand College of Radiologists, Faculty of Radiation Oncology in 2000. After working as a consultant radiation oncologist at PeterMac for several years he moved to the Princess Alexandra Hospital in 2004.

Professional Committees and Organisations

Professor Porceddu has been the President of the Clinical Oncology Society of Australia (COSA), the peak organisation for cancer-related health professionals, and the Trans Tasman Radiation Oncology Group (TROG), one of the largest cancer collaborative trials group in Australia/New Zealand. He has served on numerous national and international professional and academic committees including the board of the Cancer Council of Australia, the National Cancer Expert Reference Group for the Commonwealth and the International Union for the Control of Cancer (UICC) TNM Expert Advisory Panel.

Currently, he is the Chair of the Cancer Council Queensland Co-operative Oncology Group, a committee that provides over $1.2M per annum to support clinical research throughout Queensland and is on the board of the of the Head and Neck Cancer InterGroup (HNCIG), a group of leading world cancer experts dedicated to promoting the global harmonisation of head and neck cancer research and treatment.

Academic Highlights

Professor Porceddu runs an active clinical research program with over 150 peer-review articles, book chapters, published abstracts, invited reviews and commentaries. He has received invitations to speak at major international conferences such as the American Society of Clinical Oncology (ASCO) meeting and publish in prestigious journals such as the Lancet Oncology and Journal of Clinical Oncology.

Awards

Trans Tasman Radiation Oncology Group Outstanding Contribution

American Head and Neck Society Chris O’Brien Travelling Scholar

Pre-eminent status by Queensland Health

Rouse Fellowship, Royal Australian and New Zealand College of Radiologists

Teaching

Dr Porceddu has had a life-long commitment to teaching and is a supervisor and mentor to Doctor of Philosophy and Master of Philosophy candidates, Clinical Research Fellows, MBBS Honours students, resident, registrars and other allied health professionals.

Dr Melinda Protani is an epidemiologist with over 15 years experience in research and tertiary education. She is the current Program Director for the Master of Epidemiology at UQ. Her research is focussed on cancer aetiology, survivorship and patterns of care, with a particular interest in inequity in access to health services and the receipt of optimal cancer care. Dr Protani has experience in a number of methods including medical record audits, surveys of the general population, patient groups and clinicians, and data linkage using registry and administrative datasets.

Breast and Endocrine Surgeon, Mater Hospitals South Brisbane.

Previous Fellowships at University of Nottingham(UK) and Mayo Clinic (USA)

Chairman, Foundation for Breast Cancer Care

Senior Surgeon Breast Screen Qld Metro south Brisbane

I am a Principal Investigator (PI) and a senior research officer (SRO) at Mater research – UQ with excellent clinical and research laboratory skills and expertise in conducting and analyzing laboratory assays and resolving complex research and clinical laboratory problems. I can describe myself as determined, reliable, studious, conscientious, attentive, industrious, diligent, and focused on the timely, quality completion of all lab procedures. I am able to work well under pressure and time constraints within high-volume environments both independently and in collaboration within a team. I am also a highly self-motivated and career-oriented individual with a genuine interest in addressing cancer molecular mechanisms with the goal of developing novel cancer therapeutics and immunotherapy focusing on tumor microenvironment, immunoregulation and signaling pathways in cancer and metastasis.

Associate Prof Amy McCart Reed holds a PhD in molecular biology from The University of Queensland. She is a Fellow of the Faculty of Science of the Royal College of Pathologists Australasia. Her early postdoctoral work focused on understanding the genetic basis of colorectal cancer using experimental disease models, as part of a Cancer Research UK-funded colorectal cancer program led by Professors Ian Tomlinson and Andrew Silver. After returning to Australia, she was recruited to the Molecular Breast Pathology group at UQ’s Centre for Clinical Research and has undertaken a series of studies investigating the genomic landscape of breast cancer special types. Amy's research program includes studies on Metaplastic breast cancer and Invasive Lobular Carcinoma, two breast cancer special types in need of targetted therapy options. A/Prof McCart Reed is the scientific lead on an MRFF-funded genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, 'Q-IMPROvE'. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.

Matthew J. Roberts, BSc, MBBS, PhD, FRACS (Urol)

• Consultant Urologist, Royal Brisbane and Women’s (RBWH), Surgical Treatment and Rehabilitation Service (STARS), Queensland Health
• Clinician Research Fellow, Metro North Hospital and Health Service
• Group Leader & Associate Professor, The University of Queensland Centre for Clinical Research

Matthew is a medical graduate of The University of Queensland and completed Urology specialty training in Queensland and New South Wales. He completed his PhD under the supervision of Professor “Frank” Gardiner investigating new biomarkers for the early detection and characterization of prostate cancer.

Matthew is a surgeon-scientist, working clinically as a urologist and robotic surgeon at RBWH & STARS with academic appointment as Clinician Research Fellow at Metro North Health (Qld) and Associate Professor at UQCCR. His clinical and research interests are in Urologic cancers (e.g. prostate cancer), focusing on novel imaging and biomarkers, clinical trials, urological infections and innovation in urology. He has authored over 140 peer reviewed manuscripts in international journals and presented research at more than 20 international urology and clinical cancer meetings. He is a member of the EAU Prostate Cancer Guidelines Committee, Prostate Cancer Outcomes Registry (PCOR)-Queensland Steering Committee, Editorial Board of the BJU International, as well as Co-Convenor of the ANZUP 2024 ASM.

Dr Melanie Robitaille is a Senior Post-Doctoral Researcher working with the Calcium Signalling in Therapeutics Team (CaSTT) in the School of Pharmacy. This team specializes in the development and application of novel methodologies and cellular assays in drug discovery, including the use of genetically encoded indicator for high-content imaging in live cells.

Her interests are to elucidate how calcium signals are remodelled in disease states, to identify calcium transporters as new therapeutic targets and to develop molecular and cellular screening tools to be used in drug development programs. She has an established profile in cellular and molecular biology, with high expertise in plasmid cloning, lentiviral transduction and the use of CRISPR/Cas9 to modulate gene expression.

A/Prof Barbara Rolfe is a Group Leader at the Australian Institute for Bioengineering and Nanotechnology. A/Prof Rolfe is an immunologist and cell biologist, whose major research interests are the role of the innate immune system in cancer, the identification of novel therapeutic strategies for cancer, and nanomaterial safety. Her research has led to the identification of a previously unknown mechanism by which dysregulation of the immune system contributes to cancer development and growth, and provided information regarding the immune response to nanomaterials and the influence of physicochemical characteristics on biodistribution and cellular uptake. A/Prof Rolfe has used mouse models and small peptide agonists and antagonists to investigate the role of the innate immune system in tumour development and growth. This research demonstrated for the first time an important role for complement proteins in promoting tumour growth via regulation of immunosuppressive innate immune cells. Ongoing research is aimed focussed on gaining a better understanding of the role of complement proteins in tumour growth, developing novel immunotherapeutic strategies for cancer and investigating the application of nanomaterials for targeted delivery of anti-cancer drugs.

Dr Jodi Saunus is a senior fellow who specialises in translational research on metastatic breast cancer. Based at Brisbane’s Translational Research Institute, she was recruited by Mater Research in 2022 to help facilitate patient-focused research at the interface of biomedical R&D and clinical practice.

Dr Saunus has an honours degree in biochemistry and biomedical science, a PhD in breast cancer molecular genetics, and broad post-doctoral experience in immunology, molecular cell biology, pathology informatics, and early-phase investigator-initiated clinical trials. Her current portfolio focuses finding new ways to improve the clinical management of aggressive breast cancer, with a focus on triple-negative breast cancer, and the prevention and treatment of brain metastases. This work spans across multiple disciplines and capabilities, and broadly involves:

• Molecular profiling of patient-donated blood and tumour tissue samples to identify features that can predict treatment response, or represent previously uncharacterised therapeutic targets.
• Using experimental models of breast cancer metastasis to learn about the molecular mechanisms exploited by cancer cells to survive and grow in brain tissue.
• Developing innovative treatment strategies that work differently to conventional cancer drugs, including alpha-particle endoradiotherapy and in-situ vaccination.

With an outstanding network of collaborators from academia and clinical practice, she has secured more than $6M to fund this work and has a track record of publishing in prominent biomedical research journals (e.g., Cancer Research, Nature, Science Translational Medicine, Nature Communications and The Journal of Pathology).

Peripherally, Jodi is a strong proponent of biospecimen banking, and clinician and consumer engagement in translational research.

Dr Abbas Shafiee is a tissue engineering & regenerative medicine scientist interested in translational cell-based and tissue engineering strategies to treat human diseases.

Dr Shafiee completed his PhD in Professor Kiarash Khosrotehrani’s laboratory on stem cell biology. His research career during his PhD had key contributions to delineating endothelial niche and vascular stem cells in the human placental tissues, including the seminal discovery of an entirely new stem cell population, coined as ‘Meso-Endothelial Bipotent Progenitor’ and the identification of key driver signatures for endothelial and bipotential progenitor function (Stem Cell Reports 2018; The FASEB Journal 2017; Stem Cells 2016; Stem Cells Translational Medicine 2015).

In 2016, he joined Distinguished Professor Dietmar Hutmacher’s team and conducted multiple projects on cancer and bone tissue engineering. Dr Shafiee has developed innovative tissue engineered models intersecting concepts from stem cell biology, cancer, and tissue engineering to study species-specific cancer bone metastasis at an unprecedented level of detail. The results of his research have been published in: International Journal of Cancer 2018; Cancers 2018; Biomaterials 2018; Bone Research 2019; Biomaterials 2019; Applied Materials Today 2020; Biomaterials 2020; and Advanced Therapeutics 2020. Utilizing the tissue engineering concept, he was able to better understand the mechanisms of human cancer bone metastasis. Additionally, he was successful in obtaining project grants, including a project grants from Cooperative Research Centers (CRC), and developed a biomimetically designed scaffolds and investigated the interactions of multipotent mesenchymal stem/stromal cell and skin progenitors with 3D printed scaffolds. The application of 3D printed constructs in acute wound models decreased wound contracture and led to a significantly improved skin regeneration.

Dr Shafiee joined Metro North Health (MNH, Queensland Health) in 2020 and started a research program to develop, implement, and evaluate the applications of 3D printing, scanning, cell therapies, and biofabrication technologies in skin wound settings, and dermatology research. Using the 3D printing and organoid technologies he could develop new approaches to enhances physiological wound closure with reduced scar tissue formation (Biomaterials 2021, Small 2021, Advanced Healthcare Materials 2021, Advanced Healthcare Materials 2022) and advance the deramtology research (Advanced healthcare materials 2022, and Small 2024). Dr Shafiee is part of a national program, aiming to develop biofabrication technology to treat skin wounds (funded by MRFF, NHMRC). His groundbreaking organoid research resulted in establishing an international Consortium of Organoid Research in Dermatology, leveraging organoid technology to advance the understanding and treatment of genetic skin diseases. Dr Shafiee has supervised over 10 Masters and PhD students. Honours, Masters and PhD projects are available, please feel free to contact him.

Peter holds a BSc Honours degree and a PhD in Molecular Biology from the University of Liverpool in the UK. His first postdoctoral research position was at the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research, London UK. He moved to Australia in 2005 and helped Professor Lakhani establish the Molecular Breast Pathology group. He is a member of the International Cancer Genome Consortium (Breast Cancer group) and the Queensland Genomics Health Alliance; he is a Fellow of the Faculty of Science in the Royal College of Pathologists of Australasia. He holds a joint teaching and research position at UQ, teaching for the Discipline of Pathology on the Faculty of Medicine MD Program and is a Research Group Leader at the UQCCR.

Dr Abu Sina is currently an NHMRC Emerging Leader Fellow at the Center for Personalized Nanomedicine, Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland, Australia. Prior to this, he served as a Visiting Scientist at the Dana-Farber Cancer Institute, Harvard University, and as a Visiting Research Fellow at the Irving Cancer Research Center, Columbia University, NY, USA.

Dr. Sina has earned both national and international acclaim for his notable contributions to advancing translational-focused nano-diagnostic technologies with a focus on early cancer detection from liquid biopsies. He is one of the few leaders in the world who is driving the liquid biopsy-based multi-cancer early detection (MCED) test program. He has had several media appearances so far which include interviews on national (Channel 9, Channel 7, ABC News, Fox News, etc.) and international Television (CBC News, CTV News Canada, etc.) and Radio (4EB, 4BC, ABC Perth, ABC Sunshine coast, SBS) outlets.

Actively participating in scholarly discussions, Dr. Sina has served as a Keynote Speaker, Invited Speaker, and Session Chair at various national and international conferences and seminars. His commitment to excellence has resulted in several prestigious awards, including the Metrohm-EDRACI Young Electrochemist Award 2021, the Queensland Health and Medical Research Award 2019 from the Queensland State Government of Australia, and recognition as a Fellow of the International Association of Advanced Materials.

Central to his aspirations is a vision to develop point-of-care diagnostic technologies with the potential to revolutionize early disease detection, thereby enhancing overall quality of life.